Výsledky vyhledávání - "Strizki, J. M."

CXCR-4 (Fusin), a co-receptor for the type 1 human immunodeficiency virus (HIV-1), is expressed in the human brain in a variety of cell types, including microglia and neurons

Autor: Lavi, E., Strizki, J. M., Ulrich, A. M., Zhang, W., Fu, L., Wang, Q., O'Connor, M., Hoxie, J. A., González-Scarano, F.

Entry of the type 1 human immunodeficiency virus into most cells requires the presence of the CD4 protein in combination with one of several recently described co-receptors. CXCR-4 (fusin) was the first identified, and it serves as co-receptor for T-

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::f089657d08c9111bb108dbc5b8f6241a
https://europepmc.org/articles/PMC1858037/

Zobrazit plný text záznamu

Periodical

Piperazine-Based CCR5 Antagonists as HIV-1 Inhibitors. IV. Discovery of 1-[(4,6-Dimethyl-5-pyrimidinyl)carbonyl]- 4-[4-{2-methoxy-1(R)-4-(trifluoromethyl)phenyl}ethyl-3(S)-methyl-1-piperazinyl]- 4-methylpiperidine (Sch-417690/Sch-D), a Potent, Highly Selective, and Orally Bioavailable CCR5 Antagonist

Autor: Tagat, J. R., McCombie, S. W., Nazareno, D., Labroli, M. A., Xiao, Y., Steensma, R. W., Strizki, J. M., Baroudy, B. M., Cox, K., Lachowicz, J., Varty, G., Watkins, R.

Publikováno v: Journal of Medicinal Chemistry; May 2004, Vol. 47 Issue: 10 p2405-2408, 4p

Zobrazit plný text záznamu

Periodical

Synthesis, SAR, and Biological Evaluation of Oximino-Piperidino-Piperidine Amides. 1. Orally Bioavailable CCR5 Receptor Antagonists with Potent Anti-HIV Activity

Autor: Palani, A., Shapiro, S., Josien, H., Bara, T., Clader, J. W., Greenlee, W. J., Cox, K., Strizki, J. M., Baroudy, B. M.

Publikováno v: Journal of Medicinal Chemistry; July 2002, Vol. 45 Issue: 14 p3143-3160, 18p

Zobrazit plný text záznamu

Periodical

Piperazine-Based CCR5 Antagonists as HIV-1 Inhibitors. II. Discovery of 1-[(2,4-Dimethyl-3-pyridinyl)carbonyl]-4- methyl-4-[3(S)-methyl-4-[1(S)-[4-(trifluoro- methyl)phenyl]ethyl]-1-piperazinyl]- piperidine N1-Oxide (Sch-350634), an Orally Bioavailable, Potent CCR5 Antagonist

Autor: Tagat, J. R., Steensma, R. W., McCombie, S. W., Nazareno, D. V., Lin, S.-I., Neustadt, B. R., Cox, K., Xu, S., Wojcik, L., Murray, M. G., Vantuno, N., Baroudy, B. M., Strizki, J. M.

Publikováno v: Journal of Medicinal Chemistry; October 2001, Vol. 44 Issue: 21 p3343-3346, 4p

Zobrazit plný text záznamu

Periodical

Coupled PCR-restriction enzyme analysis for rapid identification of structural gene relationships among strains of eastern equine encephalitis virus

Autor: Strizki, J. M., Repik, P. M.

Publikováno v: Virus Research; 1996, Vol. 43 Issue: 1 p69-76, 8p

Zobrazit plný text záznamu

Periodical

A monoclonal antibody (12G5) directed against CXCR-4 inhibits infection with the dual-tropic human immunodeficiency virus type 1 isolate HIV-1(89.6) but not the T-tropic isolate HIV-1(HxB)

Autor: Strizki, J M, Turner, J D, Collman, R G, Hoxie, J, González-Scarano, F

Publikováno v: The Journal of Virology; July 1997, Vol. 71 Issue: 7 p5678-5683, 6p

Zobrazit plný text záznamu

Periodical

Infection of primary human microglia and monocyte-derived macrophages with human immunodeficiency virus type 1 isolates: evidence of differential tropism

Autor: Strizki, J M, Albright, A V, Sheng, H, O'Connor, M, Perrin, L, González-Scarano, F

Publikováno v: The Journal of Virology; November 1996, Vol. 70 Issue: 11 p7654-7662, 9p

Zobrazit plný text záznamu

Akademický článek

Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1.

Autor: Strizki, J. M., Remblay, C., Xu, S.

Publikováno v: Journal of Viral Entry; Mar2006, Vol. 2 Issue 1, p24-25, 2p

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Vyhledávací nástroje:

Upřesnit hledání